US FDA approves Pfizer’s next-generation pneumococcal vaccine
(Reuters) – The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc’s next-generation vaccine to prevent pneumococcal disease in children aged six weeks to 17 years, the company said…